Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma.
about
From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myelomaThe role of SLAMF7 in multiple myeloma: impact on therapy.Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment.Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain productionNovel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy.Determination of intrarenal resistance index (RI) in patients with multiple myeloma.The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.Early Application of High Cut-Off Haemodialysis for de-Novo Myeloma Nephropathy is Associated with Long-Term Dialysis-Independency and Renal Recovery.Immunoglobulin A multiple myeloma with cutaneous involvement in a dog.Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantationA pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysisThe Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.State-of-the-Art Management of Complications of Myeloma and Its Treatment.Guidelines for the diagnosis and management of multiple myeloma 2011.Circulating monoclonal light chains and acute kidney injury: the role of the renal biopsy with emphasis on ultrastructural evaluation in assessing and understanding renal injury.Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.Renal impairment in multiple myeloma: presenting features in different departments.Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide.The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPBendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities.Multiple myeloma and kidney disease.Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal FunctionFour structural risk factors identify most fibril-forming kappa light chains
P2860
Q26862828-DE93BA10-CEA3-484E-A27C-DBB9B20D9C5AQ30249167-8169054E-4FDA-4E4F-B135-F61BBF2DA1D5Q30595175-43CA9548-C42C-4450-B792-A03F7C84D102Q33426615-1021C54A-46F4-488B-A57A-CDB3028199F9Q35557435-33983120-11D2-48C8-99C9-E26E842A490DQ35664315-2A0FD592-88C3-4990-8DAD-6E12DB68A50DQ35959002-592842E1-6B3C-4962-A7A3-71B96D4D3FA6Q35959247-1F36D700-6FAA-4076-8021-6CF76DE868E7Q36033448-8EA445F9-3E93-45B7-B9D7-2976F038704CQ36556014-D1E78A9E-DF8D-49F2-844A-D161F65EE18AQ36725840-BD522B79-924A-417D-9209-C087E2C5AC87Q36945333-8F9BEE41-8CC7-4D48-9783-E3FE842E3F99Q37375516-49B9729A-9EB0-478D-AF82-5387C69D3C23Q37644252-4BAAE8FD-7C39-4BEE-AE9B-50121A15F538Q37776662-F2FE1A6A-A327-477B-A8F9-9024F7064A03Q37875193-7CCA87AB-943D-418D-9BD7-81270C959695Q38412536-16877569-A0D6-47C1-8012-D3BAEAED769CQ41714892-9B2E06DF-5464-4222-BCC9-9FFCC1AF8D26Q44355194-ED0BA243-8769-43BF-A8C3-32DA9D053D11Q45061083-074C814B-AE27-429A-B9B8-67C39774C45EQ45787936-124FDDD2-DD58-4989-8049-882D717EDD77Q45892519-D3A47175-C29B-4BEC-9C1E-7EBDEC54C536Q46804697-D0298254-1C44-40B1-87A8-85BD148D325DQ47562792-5521896E-13DA-4036-9A82-9E725D39C873Q54518612-AB9AFF75-70EF-49DD-AAFC-FAFDD02B6465Q56832283-AEEF1084-FBDD-4F10-8BE4-7F5BFF06AEDEQ58182078-5EBDF9C6-952C-4CC4-8FBF-6C7159CBEB3F
P2860
Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Renal failure and multiple mye ...... agement of underlying myeloma.
@ast
Renal failure and multiple mye ...... agement of underlying myeloma.
@en
type
label
Renal failure and multiple mye ...... agement of underlying myeloma.
@ast
Renal failure and multiple mye ...... agement of underlying myeloma.
@en
prefLabel
Renal failure and multiple mye ...... agement of underlying myeloma.
@ast
Renal failure and multiple mye ...... agement of underlying myeloma.
@en
P2093
P1433
P1476
Renal failure and multiple mye ...... agement of underlying myeloma.
@en
P2093
P356
10.1016/S0268-960X(99)90014-0
P577
1999-06-01T00:00:00Z